MRT-2359

MRT-2359 is a potent and orally bioavailable molecular glue degrader of GSPT1. MRT-2359 has shown significant research potential in treating MYC-driven tumors, such as lung cancer.

低至 ￥ 508 /1mg

Orforglipron

低至 ￥ 599 /5mg

KT-474

KT-474 is a potent, selective, orally bioavailable IRAK4 degrader. It targets and promotes the degradation of IRAK4 protein, thereby intervening in its role in autoimmune diseases. KT-474 has shown potential in treating a range of diseases, including autoimmune disorders.

低至 ￥ 485 /1mg

Sotorasib/索托拉西布

Sotorasib is a KRAS G12C inhibitor with an IC50 value of 5.3 nM for KRAS G12C. Sotorasib has antitumor effects and can be used in research on KRAS mutation-associated cancers.

低至 ￥ 643 /5mg

MRTX1133

低至 ￥ 2692 /10mg

Emavusertib

CA-4948 is a selective and orally bioavailable IRAK4 Inhibitor. It exhibited desirable ADME and PK profiles including good oral bioavailability in mice, rat, and dog and showed >90% tumor growth inhibition in relevant tumor models with excellent correlation with in vivo PD modulation.

低至 ￥ 300 /5mg

Zabedosertib

低至 ￥ 260 /1mg

Zimlovisertib

Zimlovisertib (PF-06650833) is an effective, selective, and orally bioavailable inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4) with an IC50 of 0.2 nM, and an IC50 of 2.4 nM in PBMC assays. Zimlovisertib has potential for research in rheumatoid arthritis, lupus, and lymphoma.

低至 ￥ 4096 /100mg

Danuglipron

PF-06882961 is a GLP-1R agonist. It works as a candidate drug for treatment for Type 2 Diabetes Mellitus in Phase 2 study.

低至 ￥ 294 /1mg

Eragidomide

低至 ￥ 549 /10mg